Acrivon Therapeutics, Inc.·4

Nov 16, 7:41 PM ET

Gamelin Erick 4

4 · Acrivon Therapeutics, Inc. · Filed Nov 16, 2023

Insider Transaction Report

Form 4
Period: 2023-11-14
Gamelin Erick
Chief Development Officer
Transactions
  • Tax Payment

    Common Stock

    2023-11-14$5.08/sh1,395$7,08718,635 total
Footnotes (1)
  • [F1]Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Documents

1 file
  • 4
    form4.xmlPrimary